CBDMT, The Market and Business Intelligence Company Reviews The
Alzheimer's Disease Market
According to CBDMT, the market and business intelligence company, the Alzheimer's disease
(AD) market was valued at $5.5 billion in 2009. The AD market is led by North America with a
market share of 52% accounting for sales of $2.8 billion. The Alzheimer disease market could
account for more than $10.1 billion by 2020.
Paris, France (PRWEB) June 1, 2010 -- Alzheimer's disease (AD) is by far the most common cause of dementia
associated with aging. It accounts for more than 60% of all dementia. Today, more than 20.8 million people are
affected by the disease around the world. As the 'baby boomer' generation ages in developed countries, the
percentage of the population aged 65 and over will increase to 716.4 million by 2020. The Alzheimer's disease
patient population is forecast to be up to 31.3 million.
Today, there are two main classes of marketed Alzheimer's disease drugs: acetylcholinesterase inhibitors and
N-methyl-D-aspartate (NMDA) receptor antagonists. Both have an action on cognitive impairments, but they do
not directly cure AD. Four different compounds are on the market, three of those are acetylcholinesterase
inhibitors: donepezil (Aricept), galantamine (Razadine, Reminyl) and rivastigmine (Exelon, Prometax). The only
one which belongs to NMDA receptor antagonist therapeutic class is memantine (Akatinol, Axura, Ebixa,
In 2009, 247 drugs were under development from discovery (92 products), preclinical (46 products), clinical
phase 1 (52 products), clinical phase 2 (50 products) to clinical phase 3 (with 7 products). Seven products were on
the market. The top 5 pharmaceutical companies in this market are Eisai, Forest Pharmaceutical, Novartis, Pfizer,
and Johnson & Johnson.
Alzheimer treatment is and will be a key pharmaceutical business. According to CBDMT, the market and
business intelligence company, the Alzheimer's disease market was valued at $5.5 billion in 2009. The only
generics on the m